The government’s advisory body Joint Committee on Vaccination and Immunisation (JCVI) on Monday issued its recommendation, advising that children “at increased risk of serious COVID-19 disease” are offered the vaccine.
The Pfizer-BioNTech vaccine is currently the only CCP virus vaccine that’s authorised for use on children over 12-year-old.
The groups the JCVI advised to be given the vaccine are children aged 12 to 15 with severe neuro disabilities, Down’s syndrome, immunosuppression, and multiple or severe learning disabilities.
Children aged 16 to 17 with underlying health conditions have already been offered vaccination under existing recommendations.
The JCVI also recommended children aged 12 to 17 get vaccinated if they live with an immunosuppressed person, as well as young adults who are about to turn 18 in three months “to ensure good uptake in newly turned 18-year-olds.”
The committee said that U.S. clinical trials suggested side effects in children aged 12 to 15 were “generally short lived and mild to moderate.”
The JCVI said they currently hold the view that the “minimal health benefits of offering universal COVID-19 vaccination to children do not outweigh the potential risks,” but Javid said the JCVI will “continue to review new data, and consider whether to recommend vaccinating under-18s without underlying health conditions at a future date.”
Office data said fewer than 30 children have died because of COVID-19 in the UK as of March this year.
But some scientific experts have spoken out on the rush to vaccinate children with COVID-19 vaccines, saying that there needs to be more safety data.
The inventor of mRNA vaccine technology, Dr. Robert Malone, said that the risk-benefit ratio for children to get vaccinated doesn’t “look so good.”